• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Drug blocked by European regulators improves quality of life for MS patients

August 18, 2017 By Sarah Faulkner

PillsA study by researchers at the Queen Mary University of London has found that a drug blocked by European regulators can improve the quality of life for people with multiple sclerosis.

The team of researchers reached this conclusion after uncovering previously unpublished clinical trial data from the European Medicines Agency. The European Commission is currently considering whether it will reverse its decision to deny a license for the oral formulation of the drug, cladribine.

Injectable cladribine is traditionally licensed as a therapy for certain cancers. But a 1,326-patient trial that enrolled people with MS found that it was highly effective in controlling relapses, lesions in the brain and the progression of disability.

The EMA rejected license applications from cladribine’s unnamed drug manufacturer, which stopped commercial development of the drug back in 2011. The researchers said the license was denied for a number of reasons, including an increase in cancer risk. The team pointed out that later research showed that the increase in cancer risk was an anomaly.

“Cladribine seemed to have such excellent potential as a treatment for MS that we thought it was tragic the development programme was shelved, and significant parts of the clinical trial data remained unpublished,” lead researcher Dr. Klaus Schmierer said in prepared remarks.

“In addition to the drug being highly effective, well tolerated, and safe as far as short term studies can show, we now know it also improves patients’ quality of life. The new results seemed so clear, we felt it was extremely important to publish and share these data.”

The researchers’ analysis evaluated quality-of-life data collected from a self-completed questionnaire. The questionnaire included topics like the patient’s mobility, self-care, pain, anxiety and activity.

After almost two years, the patients taking cladribine reported significantly improved quality-of-life scores compared to patients taking a placebo.

The drug also doesn’t seem to be linked with any severe adverse effects, the researchers reported.

In June, after researchers demonstrated that cladribine does not hieghten a patient’s risk of cancer, the EMA adopted a positive opinion for oral caldribine as a treatment for highly active relapsing MS. The European Commission, which is currently considering the EMA’s recommendation, is slated to announce its decision soon.

See the best minds in medtech live at DeviceTalks Boston on Oct. 2. 

Filed Under: Featured, Pharmaceuticals, Regulatory/Compliance Tagged With: queenmaryuniversityoflondon

IN CASE YOU MISSED IT

  • Abbott will spend $450M to up FreeStyle Libre production in Ireland
  • Better Therapeutics Q2 beats Street as it prepares to submit diabetes therapy for FDA review
  • Study backs Fluidx embolic device for vessel filling
  • Senseonics stock is up as it sticks by revenue guidance
  • Rapid Dose closes first tranche of $5M financing

Primary Sidebar

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Need Drug Delivery Business News in a minute? We Deliver!
Drug Delivery Enewsletters get you caught up on all the mission critical news you need in med tech. Sign up today.

Signup for the newsletter

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing & Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts
Add us on FacebookFollow us on TwitterConnect with us on LinkedIn

Copyright © 2022 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Advertise | Privacy Policy | RSS